LIBROS
Deftos LJ. Clinical essentialsof calcium and skeletal disorders. Caddo: ProfessionalCommunications, 1998.
Body JJ, ed. Tumor bonediseases and osteoporosis in cancer patients. Pathophysiology,diagnosis and therapy. New York: Marcel Dekker, 1999.
Sitruk-Ware C, Mishell DR, eds.Progestins and antiprogestins in clinical practice. Basel: MarcelDekker, 1999.
NÚMEROSMONOGRÁFICOS
Drezner MK. Proceedings delThird International Symposium on Paget's Disease, 1998. J BoneMiner Res 1999; 14 (Supp. 2): 1-104.
Avioli LV, ed. Symposium onAlfacalcidol. New aspects of a physiological anti-osteopatictherapy. Calcif Tissue Intern 1999; 65: 292-343.
NUESTROSAUTORES
Estepa JC, Aguilera E,López I, et al. Effects of phosphate on parathyroid hormonesecretion in vivo. J Bone Miner Res 1999; 14:1.848-1.854.
Gómez C, Naves ML,Barrios Y, et al. Vitamin D receptor gene polymorphisms, bone mass,bone loss and prevalence of vertebral fracture: Differences inpostmenopausal women and men. Osteoporosis Int 1999; 10:175-182.
Rodríguez A,Díaz-Miguel C, Vázquez M, et al. Mediciónultrasónica del hueso en mujeres sanas y factoresrelacionados con la masa ósea. Med Clin (Barc) 1999; 113:285-289.
Roig Escofet D, Roig VilasecaD. Diagnóstico de osteoporosis: utilidad y criterios deprescripción. Cienc Ginecol 1999; 5: 215-223.
Bachiller FJ, Morales AA,Arribas P, et al. Correlación y concordancia entre losvalores de hidroxiprolina total y la de piridinolinas en pacientescon enfermedad de Paget. Rev Esp Reumat 1999; 26: 75-81.
Rodríguez JP, Garat S,Gajardo H, et al. Abnormal osteogenesis in osteoporotic patients isreflected by altered mesenchymal stem cells dynamics. J Cell Biol1999; 75: 414-423.
Se ruega a los autoresenviar una copia del trabajo para incluir su cita en estasección.
REVISIONES
Chiechi LM. Dietaryphytoestrogens in the prevention of longterm postmenopausaldiseases. Int J Ginecol Obstet 1999; 67: 39-40.
Barnes GL, Kostenuik PJ,Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracturerepair. J Bone Miner Res 1999; 14: 1.805-1.815.
Baker SS, Cochram WJ, FloresCA, et al. American Academy of Pediatrics. Committee on Nutrition.Calcium requeriments of infants, children and adolescents.Pediatrics 1999; 104: 1.152-1.157.
Gennat HK, Cooper C, Poor G, etal. Interim report and recommendations of the World HealthOrganization task-force for osteoporosis. Osteoporosis Int 1999;10: 259-264.
Hauge E, Mosekilde L, Melsen F.Missing observations in bone histomorphometry on osteoporosis.Implications and suggestions for an approach. Bone 1999; 25:389-396.
Ensrud KE, Stone K, Cauley JA,et al. Vitamin D receptor gen polymorphisms and the risk offractures in older women. J Bone Miner Res 1999; 14:1.637-1.645.
Cooper GS. Genetic studies ofosteoporosis: What have we learned? J Bone Miner Res 1999; 14:1.646-1.648.
Utiger RD. Treatment of primaryhyperparathyroidism. N Engl J Med 1999; 341:1.301-1.302.
Miller PD, Daniel T, Baran JP,et al. Practical clinical application of biochemical markers ofbone turnover: Consensus of an expert pannel. J Clin Densitom 1999;2: 323-342.
Seibel MJ, Woitge HW. Basicprinciples and clinical applications of biochemical markers of bonemetabolism: Biochemical and technical aspects. J Clin Densitom1999; 2: 299-322.
Ross PD. Predicting bone lossand fracture risk with biochemical markers: a review. J ClinDensitom 1999; 2: 285-294.
Anderson JJB. Plant-based dietsand bone health: nutritional implications. Am J Clin Nutr 1999; 70:539S-542S.
Miller PD. Management ofosteoporosis. Adv Int Med 1999; 44: 175-208.
Berenbson JR, Lipton A.Bisphosphonates in the treatment of malignant bone disease. Ann RevMed 1999; 50: 237-248.
McNagry SE. Prescribing hormonereplacement therapy for menopausal symptoms. Ann Int Med 1999; 131:605-616.
Wallach W, Rousseau G, MartinL, Azria M. Effects of calcitonin on animal and in vitromodels of skeletal metabolism. Bone 1999; 25: 509-516.
Howell SJ, Shalet SM.Etiolog-specific effect of premature ovarian failure on bone mass -is a residual ovarian function important? Clin Endocrinol 1999; 51:531-534.
Chiechi LM. Dietaryphotoestrogens in the prevention of longterm postmenopausaldiseases. Int J Gynecol Obstet 1999; 67: 39-40.
Crammey A, Coyle D, Welch U, etal. Current controversies in cost effectiveness analysis ofosteoporosis therapies. J Rheumatol 1999; 26:2.300-2.302.
Sahoto O, Masud T.Osteoporosis: facts, fiction, fallacy and the future. Age Ageing1999; 28: 425-428.
Riggs BL, Khosla S, Melton LJ.The assembly of the adult skeleton during growth and maduration:implications for senile osteoporosis. J Clin Invest 1999; 104:671-672.
Bryant RJ, Cadogan J, WeaverCM. The new dietary reference intakes for calcium: implications forosteoporosis. J Am Coll Nutr 1999; 18: (Supp. 5):406-412.
Siddiqui NA, Shetty KR, DuthieEH. Osteoporosis in older men: discovering when and how to treatit. Geriatrics 1999; 54: 20-28.
Heer M, Kamps N, Biener C, etal. Calcium metabolism in microgravity. Eur J Med Res 1999; 4:357-360.
Frost HM. On the trabecular"thickness" - number problem. J Bone Miner Res 1999; 14:1.816-1.821.
OTROS ARTÍCULOSDE INTERÉS
Bikle DD, Halloran BP. Theresponse of bone to unloading. J Bone Miner Res 1999; 14:233-244.
Campanello M, Herlitz H,Lindstedt G. Determinants of bone loss in patients with Kock ilealurinary reservoir. Scand J Urol Nephrol 1999; 33:312-316.
Parker CR, Freemont AJ,Blackwell PJ, et al. Cross-sectional analysis of renaltransplantation osteoporosis. J Bone Miner Res 1999; 14:1.943-1.951.
Gluer CC. Monitoring skeletalchanges by radiological techniques. J Bone Miner Res 1999; 14:1.952-1.962.
Melton LJ, Atkinson EJ, CoperC, et al. Vertebral fractures predict subsequent fractures.Osteoporosis Int 1999; 10: 214-221.
Duan Y, Parfitt AM, Seeman E.Vertebral bone mass, size, and volumetric density in women withspinal fractures. J Bone Miner Res 1999; 14:1.796-1.802.
Khosla S, Melton LJ, WermersRA, et al. Primary hyperparathyroidism and the risk of fracture: apopulation-based study. J Bone Miner Res 1999; 14:1.700-1.707.
Shiraishi A, Higashi S, OhkawaH, et al. The advantage of alfacalcidiol over vitamin D in thetreatment of osteoporosis. Calf Tissue Int 1999; 65:311-316.
Stephen LJ, McLellan AR,Harrison JH, et al. Bone density and antiepileptic drugs: acase-controlled study. Seizure 1999; 8: 339-342.
Silverberg SJ, Shane E, JacobsTP, et al. A 10-year prospective study of primaryhyperparathyroidism with or without parathyroid surgery. N Engl JMed 1999; 341: 1.249-1.255.
Legrand E, Chappard D,Pascarelli C, et al. Bone mineral density and vertebral fracturesin men. Osteoporosis Int 1999; 10: 265-270.
Weger M, Deustschman H, WegerW, et al. Incomplete renal tubular acidosis in primaryosteoporosis. Osteoporosis Int 1999; 10: 325-329.
Rozenberg S, Twagirayezu P,Paesmans M, Ham H. Perception of osteoporosis by belgiam women whowork in a University Hospital. Osteoporosis Int 1999; 10:312-315.
Burgess JR, David R, GreenwayTM, et al. Osteoporosis in multiple endocrine neoplasia type 1.Arch Surgery 1999; 134: 1.119-1.123.
Landin K, Wilhelmsen L,Bengstsson BA. Postmenopausal osteoporosis is related to hormonalaberrations than to lifestyle factors. Clin Endocrin 1999; 51:387-394.
Christansen P, Steiniche T,Brizen K, et al. Primary hyperparathyroidism: effect ofparathyroidectomy on reginal bone mineral density in Danishpatients: a three-year follow-up study. Bone 1999; 25:589-596.
Kannus P, Palvanen M, Kaprio J,et al. Genetic factors and osteoporotic fractures in elderlypeople: prospective 25 year follow up of a nationwide cohort surveyof elderly Finnish twins. Brit Med J 1999; 319:1.334-1.337.
Haworth CS, Selby PL, Webb AK,et al. Low bone mineral density in adults with cystic fibrosis.Thorax 1999; 54: 961-967.
Scutellas V, O'Neil TW, Lunt M,et al. Does the presence of postmenopausal symptons influencesusceptibility to verteral deformity? European VertebralOsteoporosis Study (EVOS) Group. Maturitas 1999; 32:178-187.
Wei JT, Gross M, Jaffe CA, etal. Androgen deprivation therapy for prostate cancer results insignificant loss of bone density. Urology 1999; 54:607-611.
Payne JB, Reinhardt RA,Nummikoski PV, Patil KD. Longitudinal alveolar bone loss inpostmenopausal osteoporotic/osteopenic woman Osteoporosis Int 1999;10: 34-40.
Lindsay R, Cosman F, Lobo RA,et al. Adition of alendronate to ongoing hormone replacementtherapy in the treatment of osteoporosis: a randomized, controlledclinical trial. J Clin Endocrinol Metab 1999; 84:3.076-3.081.
Alensandersen P, Riis BJ,Christiansen C. Monofluorophospahte combined with hormonereplacement therapy induces a synergistic effect on bone mass bydissociating bone formation and resorption in postmenopausal women:a randomized study. J Clin Endocrinol Metab 1999; 84:3.013-3.020.
Arikoski P, Komulainen J,Riikonen P, et al. Alterations in bone turnover and impaireddevelopment of bone mineral density in newly diagnosed childrenwith cancer: a 1-year prospective study. J Clin Endocrinol Metab1999; 84: 3.174-3.181.
Backos M, Rai R, Thomas E, etal. Bone density changes in pregnant women treated with heparin: aprospective, longitudinal study. Human Reproduction 1999; 14:2.876-2.880.
Mannstadt M, Juppner H,Gardella TJ. Receptors for PTH and PTHrP: their biologicalimportance and functional properties. Am J Physiol 1999; 277:F665-F675.
Burgess JR, David R, GreawayTM, et al. Osteoporosis in multiple endocrine neoplasia type I:severity, clinical significance, relationship to primaryhyperparathyroidism and response to parathyroidectomy. Arch Surg1999; 134: 1.119-1.123.
Legroux-Gerto I, Blanckaert F,Solau E, et al. Causes of osteoporosis in males. A review of 160cases. Rev Rhum 1999; 66: 404-409.
Liu M, Tsuji T, Higuchi Y, etal. Osteoporosis in hemiplegic stroke patients as studied withdual-energy X ray absorptiometry. Arch Phys Med Rehabil 1999; 88:1.219-1.226.
Harris ST, Watts NB, Genant HK,et al. Effects of risedronate treatment on vertebral andnonvertebral fractures in women with postmenopausal osteoporosis: arandomized controlled trial. JAMA 1999; 282:1.344-1.352.
Reinhardt RA, Payne JB, MazeCA, et al. Influence of estrogen and osteopenia/osteoporosis onclinical periodontitis in postmenopausal women. J Periodontol 1999;70: 823-828.